Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer

Core Insights - The article discusses preliminary results from a Phase 1b study of pasritamig (JNJ-78278343), a bispecific T-cell engaging antibody, in combination with docetaxel for treating metastatic castration-resistant prostate cancer [1] Group 1: Study Results - The combination therapy demonstrated deep prostate-specific antigen (PSA) responses, indicating its potential effectiveness in treating the disease [1] - The safety profile of the treatment was reported as favorable, suggesting a manageable side effect profile for patients [1] Group 2: Future Plans - Johnson & Johnson plans to advance the therapy into Phase 3 clinical trials, indicating confidence in the drug's potential [1] - The study highlights the potential of this first-in-class therapy to expand the role of immunotherapy in prostate cancer treatment [1]